ecNumber*3.4.21.22#turnoverNumber*-999#turnoverNumberMaximum*#substrate*2-[5-Amino-2-(4-fluoro-phenyl)-6-oxo-6H-pyrimidin-1-yl]-N-(1-benzyl-2-oxo-2-thiazol-2-yl-ethyl)-acetamide#commentary*the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine#organism*Homo sapiens#ligandStructureId*2912#literature*649933#!ecNumber*3.4.21.22#turnoverNumber*-999#turnoverNumberMaximum*#substrate*more#commentary*the catalytic efficiency kcat/Km, of phospholipid vesicles containing 20 or 35% phosphatidylethanolamine and no phosphatidylserine is 5.5fold higher than that of vesicles containing 1% phosphatidylserine and no phosphatidylethanolamine#organism*Homo sapiens#ligandStructureId*#literature*649933#!ecNumber*3.4.21.22#turnoverNumber*0.00011#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T/Y177F, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00016#turnoverNumberMaximum*#substrate*Factor X#commentary*25&deg;C, pH 7.4#organism*Homo sapiens#ligandStructureId*#literature*649923#!ecNumber*3.4.21.22#turnoverNumber*0.00017#turnoverNumberMaximum*#substrate*Factor X#commentary*wild type FIXa, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.0002#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00021#turnoverNumberMaximum*#substrate*Factor X#commentary*plasma-derived FIXa, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00022#turnoverNumberMaximum*#substrate*Factor X#commentary*plasma-derived FIXa, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00023#turnoverNumberMaximum*#substrate*Factor X#commentary*25&deg;C, pH 7.4, in the presence of GIGAVLKVLTTGLPALISSWIKRKRQQ#organism*Homo sapiens#ligandStructureId*#literature*649923#!ecNumber*3.4.21.22#turnoverNumber*0.00025#turnoverNumberMaximum*#substrate*Factor X#commentary*25&deg;C, pH 7.4, in the presence of TRYLRIHPQSWVHQIALRMEV#organism*Homo sapiens#ligandStructureId*#literature*649923#!ecNumber*3.4.21.22#turnoverNumber*0.00029#turnoverNumberMaximum*#substrate*Factor X#commentary*wild type FIXa, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.0003#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00033#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T/Y177F, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00059#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.0008#turnoverNumberMaximum*#substrate*Factor X#commentary*#organism*Homo sapiens#ligandStructureId*#literature*669228#!ecNumber*3.4.21.22#turnoverNumber*0.00088#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T/Y177F/I213V/E219, FX activation in presence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00096#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410H, in the absence of factor VIIIa, at pH 7.4 and 37&deg;C; mutant enzyme E410N, in the absence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.001#turnoverNumberMaximum*#substrate*Factor X#commentary*in the presence of 0.1 mM phospholipid and 5 mM Ca2+#organism*Homo sapiens#ligandStructureId*#literature*652114#!ecNumber*3.4.21.22#turnoverNumber*0.001#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/A95aK/K98T/Y177F/I213V/E219G, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00105#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410A, in the absence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.0012#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410L, in the absence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.00127#turnoverNumberMaximum*#substrate*Factor X#commentary*wild type enzyme, in the absence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.00157#turnoverNumberMaximum*#substrate*Factor X#commentary*wild type enzyme, in the presence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.002#turnoverNumberMaximum*#substrate*Factor X#commentary*FIXa, in the absence of platelet surface#organism*Homo sapiens#ligandStructureId*#literature*667506#!ecNumber*3.4.21.22#turnoverNumber*0.0022#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant Y94F/K98T/Y177F/I213V/E219, FX activation in absence of FVIIIa#organism*Homo sapiens#ligandStructureId*#literature*709724#!ecNumber*3.4.21.22#turnoverNumber*0.00248#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410N, in the presence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.00361#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410L, in the presence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.00397#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410H, in the presence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.00399#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme E410A, in the presence of factor VIIIa, at pH 7.4 and 37&deg;C#organism*Homo sapiens#ligandStructureId*#literature*755584#!ecNumber*3.4.21.22#turnoverNumber*0.005#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*mutant enzyme FIXagamma225P#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*0.048#turnoverNumberMaximum*#substrate*Factor X#commentary*in the presence of emicizumab, pH and temperature not specified in the publication#organism*Homo sapiens#ligandStructureId*#literature*753894#!ecNumber*3.4.21.22#turnoverNumber*0.058#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*mutant enzyme FIXagamma225P, in presence of 200 mM Na+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*0.38#turnoverNumberMaximum*#substrate*Factor X#commentary*25&deg;C, pH 7.4, in the presence of phospholipid vesicle containing 79% phosphatidylcholine, 1% phosphatidylserine and 20% phosphatidylethanolamine#organism*Homo sapiens#ligandStructureId*#literature*649933#!ecNumber*3.4.21.22#turnoverNumber*0.42#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*wild type enzyme FIXa#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*0.63#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*wild type enzyme FIXa, in presence of 200 mM Na+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*0.78#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*mutant enzyme FIXagamma225P, in presence of Ca2+ and 185 mM Na+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*0.89#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*mutant enzyme FIXagamma225P, in presence of 200 mM Ca2+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*1#turnoverNumberMaximum*#substrate*Factor X#commentary*FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22&deg;C, pH not specified in the publication#organism*Homo sapiens#ligandStructureId*#literature*717800#!ecNumber*3.4.21.22#turnoverNumber*1.9#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant R165A the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*2.01#turnoverNumberMaximum*#substrate*methoxycarbonyl-D-Nle-Gly-Arg-p-nitroanilide#commentary*rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol#organism*Homo sapiens#ligandStructureId*31541#literature*95341#!ecNumber*3.4.21.22#turnoverNumber*2.1#turnoverNumberMaximum*#substrate*Factor X#commentary*in the presence of factor VIIIa, pH and temperature not specified in the publication#organism*Homo sapiens#ligandStructureId*#literature*753894#!ecNumber*3.4.21.22#turnoverNumber*2.9#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa104A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C; mutant enzyme rFIXa94A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*3.15#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*wild type enzyme FIXa, in presence of 200 mM Ca2+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*3.2#turnoverNumberMaximum*#substrate*Factor X#commentary*chimera enzyme FIXaN, in the presence of SFLLRN-activated platelets#organism*Homo sapiens#ligandStructureId*#literature*667506#!ecNumber*3.4.21.22#turnoverNumber*3.3#turnoverNumberMaximum*#substrate*Factor X#commentary*chimera enzyme FIX7EGF2, in the presence of SFLLRN-activated platelets#organism*Homo sapiens#ligandStructureId*#literature*667506#!ecNumber*3.4.21.22#turnoverNumber*3.3#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa107A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*3.38#turnoverNumberMaximum*#substrate*4-methylsulfonyl-D-Leu-Gly-Arg-p-nitroanilide#commentary*wild type enzyme FIXa, in presence of Ca2+ and 185 mM Na+#organism*Homo sapiens#ligandStructureId*4399#literature*669860#!ecNumber*3.4.21.22#turnoverNumber*3.4#turnoverNumberMaximum*#substrate*Factor X#commentary*plasma-derived FIXa, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*3.5#turnoverNumberMaximum*#substrate*Factor X#commentary*#organism*Homo sapiens#ligandStructureId*#literature*652413#!ecNumber*3.4.21.22#turnoverNumber*3.5#turnoverNumberMaximum*#substrate*Factor X#commentary*wild type enzyme, in TBS containing 0.1 mg/ml bovine serum albumin, 0.1% polyethylene glycol (PEG) 8000, and 5 mM Ca2+, at 22&deg;C, pH not specified in the publication#organism*Homo sapiens#ligandStructureId*#literature*717800#!ecNumber*3.4.21.22#turnoverNumber*3.8#turnoverNumberMaximum*#substrate*Factor X#commentary*chimera enzyme FIX7omegaloop, in the presence of SFLLRN-activated platelets#organism*Homo sapiens#ligandStructureId*#literature*667506#!ecNumber*3.4.21.22#turnoverNumber*3.8#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa105A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*4.1#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa90A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*5.08#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant N178A the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*5.2#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa91A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*5.2#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant K126A the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*5.47#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant K132A the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*5.51#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant wild-type enzyme the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*5.6#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant N129A the intrinsic tenase complex, in absence of ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*5.67#turnoverNumberMaximum*#substrate*methylsulfonyl-D-cyclohexylglycyl-Gly-Arg-p-nitroanilide#commentary*rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol#organism*Homo sapiens#ligandStructureId*31544#literature*95341#!ecNumber*3.4.21.22#turnoverNumber*6.11#turnoverNumberMaximum*#substrate*methylsulfonyl-D-hexahydrotyrosyl-Gly-Arg-p-nitroanilide#commentary*rFIXa, at pH 7.4, in the presence of 33% v/v ethylene glycol#organism*Homo sapiens#ligandStructureId*31545#literature*95341#!ecNumber*3.4.21.22#turnoverNumber*12.3#turnoverNumberMaximum*#substrate*Factor X#commentary*factor IXaAL#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*13.2#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-L-Arg-p-nitroanilide#commentary*#organism*Homo sapiens#ligandStructureId*33963#literature*652413#!ecNumber*3.4.21.22#turnoverNumber*16.6#turnoverNumberMaximum*#substrate*Factor X#commentary*mutant enzyme rFIXa89A, 5 units/ml FVIIIa and SFLLRN-activated platelets supplemented with bovine serum albumine (2 mg/ml) and 5 mM CaCl2, at 37 &deg;C#organism*Homo sapiens#ligandStructureId*#literature*669281#!ecNumber*3.4.21.22#turnoverNumber*17.5#turnoverNumberMaximum*#substrate*L-Leu-Gly-L-Arg-4-nitroanilide#commentary*FIXa/FXa chimera in which the 39-loop of the protease is replaced with the corresponding loop of FXa, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22&deg;C#organism*Homo sapiens#ligandStructureId*19573#literature*717800#!ecNumber*3.4.21.22#turnoverNumber*18.5#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 37&deg;C, recombinant wild-type enzyme, in absence of NaCl#organism*Homo sapiens#ligandStructureId*5413#literature*684024#!ecNumber*3.4.21.22#turnoverNumber*18.5#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 22&deg;C, in presence of 5 mM Ca2+#organism*Homo sapiens#ligandStructureId*5413#literature*684077#!ecNumber*3.4.21.22#turnoverNumber*19#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 22&deg;C, in presence of 5 mM Ca2+ and 0.2 M LiCl#organism*Homo sapiens#ligandStructureId*5413#literature*684077#!ecNumber*3.4.21.22#turnoverNumber*20.2#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 37&deg;C, recombinant wild-type enzyme, in presence of 0.2 M NaCl#organism*Homo sapiens#ligandStructureId*5413#literature*684024#!ecNumber*3.4.21.22#turnoverNumber*20.2#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 22&deg;C, in presence of 5 mM Ca2+ and 0.2 M NaCl#organism*Homo sapiens#ligandStructureId*5413#literature*684077#!ecNumber*3.4.21.22#turnoverNumber*20.8#turnoverNumberMaximum*#substrate*Factor X#commentary*factor IXaCH#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*21.3#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 22&deg;C, in presence of 5 mM Ca2+ and 0.2 M ChCl#organism*Homo sapiens#ligandStructureId*5413#literature*684077#!ecNumber*3.4.21.22#turnoverNumber*21.4#turnoverNumberMaximum*#substrate*L-Leu-Gly-L-Arg-4-nitroanilide#commentary*wild type enzyme, in 0.02 M Tris-HCl (pH 7.5) buffer containing 0.1 M NaCl, 0.1 mg/ml bovine serum albumin, 33% ethylene glycol, and 5 mM Ca2+, at 22&deg;C#organism*Homo sapiens#ligandStructureId*19573#literature*717800#!ecNumber*3.4.21.22#turnoverNumber*21.9#turnoverNumberMaximum*#substrate*CH3SO2-D-Leu-Gly-Arg-4-nitroanilide#commentary*pH 7.5, 22&deg;C, in presence of 5 mM Ca2+ and 0.2 M RbCl#organism*Homo sapiens#ligandStructureId*5413#literature*684077#!ecNumber*3.4.21.22#turnoverNumber*31.2#turnoverNumberMaximum*#substrate*Factor X#commentary*#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*43.9#turnoverNumberMaximum*#substrate*Factor X#commentary*factor IXaAL, platelet-bound#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*44.5#turnoverNumberMaximum*#substrate*Factor X#commentary*#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*110#turnoverNumberMaximum*#substrate*Factor X#commentary*factor IXaCH , platelet-bound#organism*Homo sapiens#ligandStructureId*#literature*95346#!ecNumber*3.4.21.22#turnoverNumber*600#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant N178A the intrinsic tenase complex, in presence of 30% ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*1000#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant R165A the intrinsic tenase complex, in presence of 30% ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*1340#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant wild-type enzyme and mutant N129A, each in the intrinsic tenase complex, in presence of 30% ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*1780#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant K132A the intrinsic tenase complex, in presence of 30% ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#!ecNumber*3.4.21.22#turnoverNumber*1999#turnoverNumberMaximum*#substrate*Factor X#commentary*pH 7.4, 22&deg;C, recombinant mutant K126A the intrinsic tenase complex, in presence of 30% ethylene glycol#organism*Homo sapiens#ligandStructureId*#literature*683165#